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The feasibility of allogeneic bone marrow transplantation (alloBMT)
in a developing country has not yet been demonstrated. Many adverse
factors including social and economic limitations may reduce the
overall results of this complex and expensive procedure. Our objective
was to characterize the most important clinical, social and economic
features of candidates for transplantation and their potential donors as
well as the influence of these factors on overall survival in a retrospec-
tive and exploratory analysis at a university hospital. From July 1993
to July 2001, candidates for BMT were referred to the Bone Marrow
Transplantation Unit by Hematology and Oncology Centers from
several regions of Brazil. A total of 1138 patients were referred to us
as candidates for alloBMT. Median age was 25 years (range: 2
months-60 years), 684 (60.1%) were males and 454 (39.9%) were
females. The clinical indications were severe aplastic anemia and
hematological malignancies. From the total of 1138 patients, 923 had
HLA-typing; 497/923 (53.8%) candidates had full match donors; 352/
1138 (30.8%) were eligible for alloBMT. Only 235 of 352 (66.7%)
were transplanted. Schooling was 1st to 8th grade for 123/235 (52.3%);
monthly family income ranged from US$60 (7%) to more than US$400
(36%). Overall survival for patients with chronic myeloid leukemia,
severe aplastic anemia and acute myeloid leukemia was 58, 60 and
30%, respectively. Thus, overall survival rates for the most frequent
hematological diseases were similar to those reported in the Interna-
tional Registry, except for acute myeloid leukemia. This descriptive
and exploratory analysis suggests the feasibility of alloBMT in a
developing country like Brazil.
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Introduction
Brazil is a developing country with about
170 million inhabitants. Most of its popula-
tion lives in the southeast and south, the
richest region of the country (1). However,
the median family income is only up to
US$300 per month, depending on the region
of the country (2). The percentage of illit-
eracy is about 13.5%, and in the poorest
regions (north and northeast) this figure may
reach 26.6% (3). To perform allogeneic bone
marrow transplantation (alloBMT) within this
reality would be a difficult task and may pose
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additional risks in terms of treatment and
socioeconomic support.
The first operating BMT unit in Brazil
began its activity in Curitiba, Parana State, in
1980 (4). However, the procedure became
available at many university hospitals mainly
in the southeast only in the 1990’s.
AlloBMT is a complex and expensive
medical procedure. In the US the median
cost of this therapy is about US$193,000 per
procedure (5). There are no data concerning
the costs of this procedure in Brazil. AlloBMT
is an important modality of treatment, in
many cases the only possibility of cure or
disease control. In many countries, bone
marrow is the second most transplanted tis-
sue (6). AlloBMT requires the cooperation
and understanding of the patients and their
families. Stress and anxiety from feelings of
uncertainty about the future and fears about
treatment must be evaluated (7). In addition,
minimal life conditions to bear the several
phases of transplant are important for the
success of the procedure (7). All relevant
information must be given to the patients
and relatives in order to obtain maximum
cooperation, independent of social or eco-
nomic conditions.
The Bone Marrow Transplantation Unit
of the State University of Campinas, São
Paulo State, performed its first transplant in
September 1993. At the beginning of the
local program, coordinators had many doubts
related to the feasibility of alloBMT in a
country such as Brazil, mainly because most
of the patients were poor and presented un-
favorable living conditions. Moreover, our
public hospital is free and responsible for
medical assistance to about 6 million people
without medical insurance living around
metropolitan Campinas (8). In this study,
our aim was to characterize the most impor-
tant clinical, social and economic features of
candidates for transplant and their potential
donors. We also intend to analyze the pa-
tients treated with alloBMT at our institu-
tion, and the influence of the most important
factors in terms of survival.
Patients and Methods
This is a retrospective and exploratory
study in which we analyzed 1138 patients
referred to our unit for alloBMT from July
1993 to July 2001. The candidates came
from different Hematology and Oncology
Centers in several states of Brazil. A prelimi-
nary form containing name, age, origin, di-
agnosis and number of possible sibling do-
nors was completed for each patient. The
first contact was made by fax, phone, letter,
or e-mail or directly from physician to
physician or through the Social Service of
the Bone Marrow Transplantation Unit. Af-
ter the first contact, candidates and donors
were called to the unit and blood from both
groups was sent to the histocompatibility
laboratory in order to confirm or exclude
donor compatibility for transplant. During
this phase, HLA loci A and B (class I) from
candidates and donors were determined.
When this analysis demonstrated full com-
patibility between candidates and donors,
class II and/or mixed lymphocyte culture
was performed (9-12).
Pre-bone marrow transplantation ambulatory
visit
The candidates with full match donors
were scheduled for a pre-BMT ambulatory
visit since they met the requirements of the
institutional protocols. First of all, a detailed
explanation about the procedure and its po-
tential complications was given to patients
and donors. At the same time all patients and
donors were evaluated for psychological
(13-19), transfusional (20), clinical and labo-
ratory conditions.
Patient eligibility criteria were as fol-
lows: age <60 years, Eastern Cooperative
Group (ECOG) performance status <2, creati-
nine clearance above 50 mg/dl, left ventricu-
lar ejection fraction more than 45%, pulmo-
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nary function (functional vital capacity) more
than 60%, negative serology for HIV and
HLTV-I, negative active B or C hepatitis
virus and absence of renal or hepatic func-
tion, no lack of a caregiver, and favorable
socioeconomic conditions. Unfavorable so-
cioeconomic conditions are defined by our
institution as living without piped or filtered
water or basic sanitation, and not having
enough money to buy adequate food, medi-
cations, transportation, etc. Our institution
provides special support to these patients,
including nourishment, transportation and
many times free lodgings near the hospital,
not only for the patients but also for their
caregivers, mainly during the first year after
transplant.
Donors’ eligibility criteria were good gen-
eral health, negative serology for HIV and
HLTV-I, negative active B or C hepatitis
virus, and no Chagas’ disease.
Peripheral blood progenitor cell donors
were also evaluated in terms of availability
of peripheral veins for apheresis when indi-
cated. Red blood cell typing was performed
and compatibility for ABO group, Rhesus
factor and subsets was determined for both
patients and donors. When all criteria were
satisfied, informed consent was obtained
from all patients and donors. The study pro-
tocols were approved by the local Ethics
Committee.
Statistical analysis
Descriptive statistics based on univariate
summaries for several variables at different
times was used. This process was first ap-
plied to all candidates, then to all candidates
eligible for transplant, and finally to the
transplanted patients, with the actuarial
curves added for this group according to the
Kaplan-Meier method (21). Overall survival
was analyzed according to years of school-
ing (up to 8 years, 8 to 12 years, more than 12
years), family income (up to US$240, from
US$241 to US$399, and above US$400),
and according to primary disease. These
analyses were performed using the SPSS
software, version 10.0 for Windows.
Results
We first analyzed 1138 candidates, 943
(83%) from São Paulo State, 95 (8.3%) from
Minas Gerais State, and 100 (8.7%) from
other states. Of these, 684 (60.1%) were
males and 454 (39.9%) were females. Me-
dian age was 25 years (range: 2 months-60
years). The main clinical hypotheses were:
317 cases (27.9%) of chronic myeloid leuke-
mia, 258 cases (22.7%) of acute myeloid
leukemia (AML), 198 cases (17.4%) of acute
lymphoblastic leukemia, 144 cases (12.7%)
of severe aplastic anemia, 67 cases (5.9%) of
myelodysplastic syndrome, 83 cases (7.3%)
of malignant lymphomas, 30 cases (2.6%) of
multiple myeloma, and 41 cases (3.5%) of
other diseases. The median number of pos-
sible donors per patient (siblings) was 3
(range 0-15). After the selection procedure
the median number of full match donors was
1 (range 1-5). For 102 (9.0%) candidates the
parents were studied in order to confirm the
HLA typing. From the total of 1138 candi-
dates, 923 had HLA-typing and 497/923
(53.8%) had full match donors and were
included in the clinical and laboratory screen-
ing for transplant; 641 (56.4%) were consid-
ered ineligible to undergo a transplant at our
unit. The characteristics of the referred and
transplanted patients are summarized in Table
1. Table 2 shows the main causes of exclu-
sion for transplant before medical evalua-
tion.
Of the 497 (53.8%) candidates who had a
full match donor as determined by HLA
typing, 145 (29.3%) were not eligible for
transplant, most of them (75, 51.7%) due to
diseases excluded by the current protocols.
The remaining 70 patients (48.3%) did not
present the clinical, psychiatric, or socioeco-
nomic conditions required for transplanta-
tion.
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Of the 352 (30.8%) candidates eligible
for transplantation, however, only 235 of the
total of 1138 candidates (20.6%) were trans-
planted. Of the 117/352 (33.2%) non-trans-
planted patients, 40 (11.4%) had died before
BMT, most of them due to hematological
diseases, 21 (6.0%) had unfavorable clinical
or socioeconomic conditions at the time of
transplant, 18 (5.1%) were lost to follow-up,
16 (4.5%) are still on line for a transplant, 9
(2.6%) were abandoned by their donors, and
5 (1.4%) were transplanted at other units.
The first transplant was performed at our
unit in September 1993. Of 235 transplanted
patients, 77% were from São Paulo State,
10% from Minas Gerais State and 13% from
other states. Sixty-four percent of the pa-
tients were males and 36% females. Sev-
enty-eight percent of patients were Cauca-
sians, 19% Afro-Brazilians and 3% Japa-
nese descendants. Median age was 29.2 years
(range: 3.3-59.3). Educational level was el-
ementary school for 123 of 235 (52.3%)
patients, incomplete in most cases. Accord-
ing to the International Bone Marrow Trans-
plantation Registry (IBMTR) standard of
scholarship, 4 patients (1.7%) were illiter-
ate, 142 (60.4%) had completed 1 to 8 grades
and 22 (9.3%) had a college degree (BS/
BA). Overall survival according to school-
ing did not differ between groups (Figure 1).
Monthly family income ranged from US$60
(7%) to more than US$400 (36%). Figure 2
shows better results for the groups with a
family income below US$400. In terms of
professional activities, 87 (37%) had a sales
occupation, 57 (24%) were students, 19 (8%)
were unemployed, and 72 (31%) worked in
other activities.
Figure 3 shows the overall 8-year sur-
vival for chronic myeloid leukemia, severe
aplastic anemia and AML, which was 58, 60
and 30%, respectively. The 8-year survival
of AML patients transplanted while in first
complete remission (N = 14) was 92%, as
opposed to 10% for patients with a first
relapse or more advanced disease (N = 26).
Table 2. Causes of exclusion of candidates/patients for allogeneic bone
marrow transplantation.
Causes No. %
Incompatibility HLA 426 66.2
Lack of HLA typing due to:
No return 113 17.5
Patient’s death 46 7.1
Diseases not included in protocols 19 3.0
No brothers 15 2.3
Donors not localized 9 1.4
Refused exams 7 1.1
Inconclusive results 6 0.9
Total of excluded patients 641 100.0
HLA, histocompatibility leukocyte antigen.
Table 1. Characteristics of patients referred and transplanted.
No. %









Malignant lymphomas 83 7.3
MDS 67 5.9
Multiple myeloma 30 2.6
Others 41 3.5
Median of brothers (range) 3 (0-15)
No. of patients with full match donors 497/923 53.8/100
Median of full match donors (range) 1 (1-5)











CML, chronic myeloid leukemia; AML, acute myeloid leukemia; ALL,
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The overall survival for other diseases is not
presented due to the small number of cases.
Discussion
Data from IBMTR have shown a con-
stant increase in the number of alloBMT
worldwide (22). However, most of these
transplants are being performed in North
America, Western Europe, Japan, and Aus-
tralia. The number of centers and transplants
performed in South America, Africa, West-
ern Europe, the Middle East, and East Asia is
very low. The proportion between inhabit-
ants and transplants performed in these re-
gions is completely unbalanced, and many
patients have no access to BMT units even
when they have donors.
In Brazil, there was a delay in the devel-
opment of BMT. The first unit performing
BMT in Brazil was set up at the University
Hospital of the Federal University of Paraná
in the early eighties. In the nineties, many
other centers began their activities. Data from
the Brazilian Registry of Transplants sug-
gest that only about 50% of patients with
donors are transplanted today. Many factors
are involved in this limit, but the most impor-
tant is the unavailability of units and of
enough beds. Most BMT centers are located
in the south or southeast region of the coun-
try, the richest regions in Brazil. Brazil is a
continental country, and travel and living
expenses outside the home are a real limita-
tion for many patients.
Among 170 million inhabitants, only 35
million have private medical insurance, while
more than 135 million depend on govern-
mental resources and structure, i.e., free
medical care. Other important considerations
are those linked to unfavorable living condi-
tion and the limited understanding ability of
patients and their families. A high percent-
age of patients have low schooling and in-
come. Nevertheless, our institution provides
extensive social support including housing,







0 365 730 1095 1460 1825 2190 2555 2920
Days
>12 years: 54% (N = 25)
P = NS







0 365 730 1095 1460 1825 2190 2555 2920
Days
US$241-399: 54% (N = 62)
>US$400: 34% (N = 65)
P = 0.003
up to US$240: 53% (N=108)
Figure 2. Overall survival according to family income.
8-12 years: 53% (N = 54)
up to 8 years: 45% (N = 156)
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0 365 730 1095 1460 1825 2190 2555 2920
Days
SAA: 60% (N = 46)
AML: 30% (N = 40)
CML: 58% (N = 100)
Figure 3. Overall survival of patients with chronic myeloid leukemia (CML), severe aplastic
anemia (SAA), and acute myeloid leukemia (AML).
thus minimizing the influence of poverty factors. Although almost 54% of
HLA-typed patients had full match donors, only 47% of them were
transplanted. This undesirable fact probably has a complex explanation
related to clinical, social, psychiatric or economic conditions, sometimes
impossible to overcome, regardless of institutional structure.
Disconcerting also is the number of donors who abandoned their
siblings or were not located (4.1%) and the number of patients progressing
and dying on the waiting line before transplant or still waiting for
transplant (16%). This is directly linked to
the small number of beds available for trans-
plant at our institution. An unexpected result
was related to family income and survival.
For reasons that we cannot explain, patients
in the lower income group presented the best
clinical results which were statistically sig-
nificant (P = 0.003). Perhaps patients in
these groups had been submitted to a favor-
able social selection before arriving at the
BMT unit.
Despite this unfavorable scenario, the
overall results obtained in this analysis were
similar to those reported by the International
Registry, except for AML (22), whose re-
sults were lower than those reported in the
literature. However, in terms of AML, our
results using alloBMT were superior to those
obtained using conventional chemotherapy
alone and very good (92%) for patients in
first complete remission prior to alloBMT at
our institution (23) and at other Brazilian
institutions (24-27). This descriptive and ex-
ploratory analysis confirms the feasibility of
alloBMT in a developing country like Brazil,
despite difficulties for patients, families and
the medical care system.
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